New postmarketing reports link Adzynma to neutralizing antibodies and a fatality, leading the FDA to evaluate the need for updated labeling.
Based on the efficacy results, Novo Nordisk has made the decision to discontinue the 1-year extension periods for these trials.
Asundexian is designed to reduce thrombus formation without increasing bleeding risk by selectively inhibiting FXIa.
Benefits of metformin outweigh risks among young people with overweight or obesity and treated with second-gen antipsychotics.
Mindfulness-based interventions beneficial for nurses, midwives, while professional coaching effective for physicians ...
HealthDay News — Health officials are warning parents that recalled ByHeart baby formula is still showing up on store shelves, even as lab tests confirm it was contaminated with dangerous bacteria ...
HealthDay News — A quadrivalent nucleoside-modified messenger RNA (modRNA) influenza vaccine is superior to a licensed inactivated quadrivalent influenza vaccine, according to a study published in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback